头孢哌酮/舒巴坦治疗下呼吸道感染的疗效及耐药趋势分析  

Effect of cefoperazone-sulbactam on treatment of lower respiratory tract infections and trend of drug resistance

作　　者：许敬菊[1] 程慎令[1] 丛晓荣[1] 

机构地区：[1]滕州市中心人民医院药学部,山东滕州277500

出　　处：《中华医院感染学杂志》2015年第1期90-92,共3页Chinese Journal of Nosocomiology

基　　金：山东省自然科学基金资助项目(ZR2012HM097)

摘　　要：目的研究头孢哌酮/舒巴坦对下呼吸道感染的抗菌效果以及耐药趋势,以降低感染率。方法选取2009年5月-2011年5月医院收治的下呼吸道感染患者80例,根据用药情况将患者分为Ⅰ组(首次应用)27例、Ⅱ组(非首次应用)28例、Ⅲ组(已应用其他抗菌药物)25例,3组患者均给予头孢哌酮/舒巴坦治疗,比较3组的抗菌效果及耐药性。结果总有效率Ⅰ组患者为92.6%、Ⅱ组患者为82.1%、Ⅲ组患者为88.0%,Ⅰ组与Ⅱ组比较差异有统计学意义(χ2=10.82,P<0.05);80例患者共分离病原菌239株,Ⅰ组81株,Ⅱ组84株,Ⅲ组74株,细菌清除率Ⅰ组为93.8%、Ⅱ组为78.6%、Ⅲ组为82.4%,Ⅰ组与Ⅱ组比较差异有统计学意义(χ2=11.82,P<0.05);239株病原菌均对头孢哌酮/舒巴坦具有敏感性,高度敏感菌为214株,占89.5%,其中Ⅰ组79株,占97.5%,Ⅱ组64株,占76.2%,Ⅲ组71株,占95.9%,Ⅰ组与Ⅱ组比较差异有统计学意义(χ2=13.01,P<0.05)。结论头孢哌酮/舒巴坦治疗下呼吸道感染具有较好的抗菌效果,细菌的耐药性呈上升趋势,与应用的次数有关。OBJECTIVE To study the effect of cefoperazone-sulbactam on treatment of lower respiratory tract infec-tions and analyze the drug resistance trend so as to reduce the infection rate.METHODS A total of 80 patients with lower respiratory tract infections who were treated in the hospital from May 2009 to May 2011 were enrolled in the study and divided into the groupⅠwith 27 cases（first use）,the groupⅡwith 28 cases（non-first use）,and the groupⅢwith 25 cases （use of other antibiotics）according to the medication status,all the three groups were treated with cefoperazone-sulbactam,and the antibacterial effect and the drug resistance were observed and compared between the three groups. RESULTS The total effective rate was 92.6% in the group Ⅰ,82.1% in the group Ⅱ,88.0% in the group Ⅲ, there was significant difference between the group Ⅰ and the group Ⅱ （χ^2=10.821,P〈0.05）.Totally 239 strains of pathogens have been isolated from the 80 patients,including 81 strains isolated from the group Ⅰ,84 strains isolated from group Ⅱ,74 strains isolated from the group Ⅲ.The bacterial clearance rate was 93.8% in the group Ⅰ,78.6% in the group Ⅱ,82.4% in the group Ⅲ,there was significant difference between the groupⅠ and the group Ⅱ （χ^2=11.821,P〈0.05）.All the 239 strains of pathogens were sensitive to cefoperazone-sul-bactam,among which 214 strains were highly sensitive to cefoperazone-sulbactam,accounting for 89.5%,inclu-ding 79（97.5%）strains from the groupⅠ,64 （76.2%）strains from the groupⅡ,and 71 （95.9%）strains from the group Ⅲ,there was significant difference between the group Ⅰ and the group Ⅱ （χ^2=13.011,P〈0.05）. CONCLUSION Cefoperazone-sulbactam can achieve significant antibacterial effect on the treatment of lower respiratory tract infections.The bacterial drug resistance shows an upward trend,which is associated with the frequency of application.

关 键 词：头孢哌酮/舒巴坦 下呼吸道感染 抗菌 耐药趋势 

分 类 号：R978.1[医药卫生—药品]